Matracell is one of the new technology platforms that the company has developed to enhance the utility and clinical effectiveness of human allograft tissue. LifeNet Health said that Matracell technology is a patented and validated process to render allograft tissue acellular, removing over 99% of the donor genetic material while retaining the native biomechanical strength of the tissue.
The CardioGRAFT decell pulmonary patch with Matracell technology is currently being implanted in four clinical centers that specialize in correcting life threatening pediatric congenital heart conditions. The sites will be generating data regarding clinical results for publication and presentation, said the company.
Rony Thomas, CEO and president of LifeNet Health, said: "We are excited to offer Matracell to surgeons across the country to help restore health to pediatric heart patients. Matracell has the potential to improve clinical outcomes and increase implant durability. We hope this will reduce the number of surgeries any child will have to undergo with this improved technology."
LifeNet Health claims that it has so far distributed over two million bio-implants, including 20,000 cardiovascular allografts, without any disease transmission.